| Literature DB >> 29038978 |
David Francis Fullon Chan1, Milagros Herrera-Arroyo2, Darby E Santiago2, Teresita R Castillo2, Ma Florentina Q Fajardo-Gomez2.
Abstract
BACKGROUND: Severe vision-impairing ocular inflammation is rarely reported following extensive laser. Previous cases have involved retinal photocoagulation for diabetic retinopathy resolving over days. This report documents a rare instance of this where encircling retinopexy/cerclage was done as fellow eye retinal detachment prophylaxis in a patient with no overt comorbidities.Entities:
Keywords: Encircling laser retinopexy; Laser cerclage; Post-laser inflammation; Retinal detachment; Retinal detachment prophylaxis; Retinal laser/photocoagulation
Year: 2017 PMID: 29038978 PMCID: PMC5643585 DOI: 10.1186/s12348-017-0139-y
Source DB: PubMed Journal: J Ophthalmic Inflamm Infect ISSN: 1869-5760
Fig. 1Day 2 post-laser B-scan ultrasound, axial horizontal, documents low amplitude vitreous echoes with good aftermovement and a prominent choroid
Fig. 2Day 4 post-laser, documents a 1.0mm blood-tinged hypopyon with accompanying best-corrrected visual acuity (BCVA) of hand motion, light perception in all quadrants
Fig. 3On Day 8 post-laser, four days following subconjunctival injection of triamcinolone acetonide, 10mg, hypopyon is seen reduced, with a marginally decreased anterior chamber cell and flare
Fig. 4On day 15 post-laser, seen are beginning nasal papillary synechiae, retrolental membranes, decreased anterior chamber reaction, homogeneous gray haze on indirect ophthalmoscopy, accompanied by BCVA of hand motion, light perception in all quadrants
Fig. 5Day 15 post-laser B-scan ultrasound, axial horizontal documents dense, mobile retrolental/anterior vitreous echoes, mobile dot echoes with increasing amplitude in the mid-posterior vitreous, and a band echo suspicious for exudative retinal detachment on the nasal wall
Fig. 6Day 15 post-laser UBM at ~8 o’clock documents ciliary body swelling, cystic morphology, and echoes occupying the space between the iris and lens
Fig. 7Day 36 post-laser. Uncorrected VA 20/70, best corrected to 20/20
Fig. 11Day 75 post-laser anterior segment slit lamp photograph, demonstrating velvety iris, pronounced pupillary synechia with anterior subcapsular cataract along its margins, persistence of anterior chamber + 1–2 cells and flare, and retrolental membranes with accompanying uncorrected visual acuity of 20/20
Fig. 8Day 56 Macular OCT demonstrates generalized macular thickening, preservation of the foveal contour, and prominent posterior hyaloid face detached over the foveal depression
Fig. 9Day 56 Fluorescein angiogram, early venous (left) and recirculation (right) phases, demonstrates non-specific parafoveal staining superiorly, with no overt delays, evidence of vasculitis, macular edema nor ischemia
Fig. 10Day 56 fundus photo
Fig. 12Day 75 post-laser anterior segment slit lamp photograph demonstrating flapping retrolental membranes viewed while on downgaze, with accompanying uncorrected visual acuity of 20/20
Chronology of major events
| Week 1 | Day 1 post-laser |
| • | |
| • + 3 brown cells, + 2 flare in anterior chamber; dense vitreous haze on dilated indirect ophthalmoscopy | |
| • IOP 20 mmHg treated eye, 10 mmHg RRD eye | |
| • Topical polymyxin + neomycin + dexamethasone shifted to prednisolone acetate 10 mg/mL q2 hours, atropine sulfate 1% 3×/day, and oral acetazolamide 125 mg 2×/day | |
| Day 2 | |
| • B-scan: low amplitude, mobile echoes in the mid to posterior vitreous, and prominent choroid (Fig. | |
| Day 4 | |
| • 1-mm blood-tinged hypopyon (Fig. | |
| • IOP of 10 mmHg | |
| • Topical prednisolone acetate increased to one drop hourly, topical moxifloxacin 5 mg/mL 6 drops q3 hours started | |
| • Subconjunctival triamcinolone acetonide (10 mg) | |
| Day 6 | |
| • Patient admitted to hospital | |
| Day 8 | |
| • Oral prednisone 60 mg daily | |
| Week 2 | • Cells and flare decreased to between + 1 and + 2, |
| • Hypopyon resolved day 13 (Fig. | |
| Week 3 | • Pupillary synechiae, iris swelling 6–12-o’clock areas; dense, mobile, gray-brown retrolental sheets/membranes (Fig. |
| • | |
| • | |
| • Oral immunosuppressive therapy, pars plana vitrectomy contemplated ➔ deferred due to stable condition, fear of pushing eye into phthisis | |
| Week 4 | • |
| • | |
| • | |
| • Fundus details first seen on indirect ophthalmoscopy day 30 | |
| Week 6 | • Oral prednisone gradually adjusted to 40–50 mg/day |
| Week 8 | • |
| • | |
| • | |
| • | |
| Week 11 | • IOP ~ 25 treated eye, 30–35 RRD eye |
| • Laser iridotomy and/or phacoemulsification contemplated ➔ deferred until resolution of inflammation | |
| • Timolol maleate 5 mg/mL 2×/day started | |
| • IOP decreased over following 2 days: 5–9 RRD eye, 17–19 treated eye (Figs. |